Time to first remission and associated factors in type 2 diabetes mellitus: a retrospective cohort study in Ethiopia.

Postoperative nausea and vomiting (PONV) is among the most common complications after anesthesia, affecting approximately one-third of surgical patients []. In addition to causing substantial patient discomfort, PONV is associated with delayed recovery, prolonged hospitalization, and increased healthcare utilization [–]. Effective prevention of PONV therefore remains a key priority in perioperative care. Opioids, particularly sufentanil, are widely used for intraoperative and postoperative analgesia because of their potent analgesic efficacy and rapid onset []. However, their clinical use is limited by dose-dependent adverse effects, most notably respiratory depression and PONV [, ]. Oliceridine is a novel µ-opioid receptor agonist designed to preferentially activate G-protein–mediated signaling while limiting β-arrestin recruitment. This biased signaling profile has been proposed to maintain effective analgesia while reducing opioid-related adverse events [, ]. However, evidence from randomized controlled trials comparing oliceridine with conventional opioids, including sufentanil, remains inconclusive [, ]. To clarify these uncertainties, we conducted a systematic review and meta-analysis to compare the effects of oliceridine and sufentanil on postoperative nausea and vomiting, with the aim of providing higher-level evidence to inform perioperative analgesic strategies.